- CKD-associated anemia:
- Initially SC/IV 0.45mcg/kg/dose every week
- Individualize dose every 1-2 weeks
- Chemotherapy-related anemia with non-myeloid malignancies:
- SC 2.25mcg/kg weekly OR SC 500mcg every 3 weeks
- Discontinue if non-responsive after 8 weeks
- Injection:
- 25mcg/0.42 mL
- 40mcg/0.40 mL
- Do not increase the dose more frequently than once every 4 weeks
- Avoid frequent dose adjustment
- When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly
- Vigorous shaking may denature the drug
Hematopoietic Growth Factors
It stimulates erythropoiesis via division & differentation of progenitor cells in the bone marrow to induce the release of reticulocytes into the bloodstream to become erythrocytes
- Infection
- Hypertension
- Hypotension
- Muscle spasms
- Myalgia
- Headache
- Diarrhea
- Nausea
- Vomiting
- URI
- Arrhythmia
- Angina
- Abdominal pain
- Dyspnea
- Peripheral edema
- Arthralgia
- Limb pain
- Fatigue
- Cough
- Fever
- Vascular access thrombosis
- Dizziness
- Back pain
- Pruritus
- Injection site pain
- Influenza-like symptoms
- Fluid overload
- Asthenia
- CHF
- Constipation
- Uncontrolled hypertension
- Hypersensitivity to class/components
- Pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs
WARNING:
Increased risk of death and serious cardiovascular events when administered to target Hb >11 g/dL
Erythropoiesis-Stimulating Agents (ESAs) shortened overall survival and/or increased the risk of tumor progression in some clinical studies in patients with breast, head and neck, lymphoid, non-small cell lung and cervical cancers
None restricted
Drug Status
Availability | Prescription only |
Pregnancy | Can be used where benefit outweighs risk |
Breastfeeding | Can be used |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Derise | 25mcg/0.42 mL | Injection | 1’s | Hetero Biopharma | Unisel Ltd |
Derise | 40mcg/0.40 mL | Injection | 1’s | Hetero Biopharma | Unisel Ltd |